Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

FDA approves obinutuzumab (Gazyva) as first-ever treatment for primary membranous nephropathy

An intricate microscopic view of plant cells showing vibrant patterns and structures through a microscope lens.
  1. The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva, Genentech) for the treatment of adults with primary membranous nephropathy (PMN) at risk of disease progression — marking the first FDA-approved therapy specifically indicated for this condition.

The approval, announced on November 13, 2026, was based on results from the Phase 3 MAJESTY trial, in which obinutuzumab demonstrated significantly higher rates of complete remission compared with the off-label standard, tacrolimus.

 

Primary membranous nephropathy is an autoimmune kidney disease in which antibodies — most commonly against the phospholipase A2 receptor (PLA2R) — attack the glomerular basement membrane, causing severe proteinuria and progressive kidney damage. Up to 30% of untreated patients progress to kidney failure within 10 years.

 

The MAJESTY trial randomized 142 adults with PMN 1:1 to intravenous obinutuzumab or oral tacrolimus for 104 weeks. Complete remission — defined as a urinary protein-to-creatinine ratio of 0.3 or lower with stable estimated glomerular filtration rate (eGFR) — was achieved in 37% of patients in the obinutuzumab group, compared with 6% in the tacrolimus group (adjusted difference: 31 percentage points; 95% CI 18–44; P < .001).

 

Obinutuzumab is a type II anti-CD20 monoclonal antibody that depletes CD20-positive B cells, including tissue-resident B cells implicated in the autoimmune pathogenesis of PMN. The drug had previously received FDA Breakthrough Therapy Designation for PMN in April 2026 and was placed under Priority Review.

 

The safety profile was consistent with known risks of obinutuzumab. Grade ≥3 adverse events occurred in 22% of patients in the obinutuzumab group versus 19% in the tacrolimus group. The prescribing information carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML).

 

Genentech noted that the MAJESTY data are being submitted to other health authorities, including the European Medicines Agency (EMA). The trial results were presented at the European Renal Association Congress in June 2026 and published in The New England Journal of Medicine.

Source: HCPLive (FDA press release, NEJM)